Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Targaprimir-96 TFA is a potent microRNA-96 (miR-96) processing inhibitor.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
100 mg | 待询 | 待询 | ||
500 mg | 待询 | 待询 |
产品描述 | Targaprimir-96 TFA is a potent microRNA-96 (miR-96) processing inhibitor. |
体外活性 | In MDA-MB-231 triple negative breast cancer cells, Targaprimir-96 TFA shows a dose-response (IC50 of ~50 nM) by assessing the reduction of mature miR-96 levels. Targaprimir-96 (50 nM) TFA boosts the amount of the pri-miRNA and decreases the levels of the pre-miRNA and mature miRNA in a dose-dependent manner. In breast cancer cell line 4175, Targaprimir-96 TFA (50 nM; 48 hours) increases FOXO1 levels and triggers apoptosis . Targaprimir-96 TFA binds RNA3 (contains both the Drosha site and the adjacent 1×1 nt GG internal loop) with a Kd of 85 nM. Targaprimir-96 binds RNA1, RNA2, RNA4, and RNA5 with Kd values of 1.2, 0.9, 1.2, and 1.5 μM, respectively. Thus, Targaprimir-96 TFA is highly RNA-selective and recognizes both the 1×1 nt GG and 1×1 nt UU loops to provide high affinity, effectively discriminating against a variety of related targets. |
体内活性 | In a mouse model of triple-negative breast cancer (TNBC), Targaprimir-96 TFA (10 mg/kg; i.p.; every other day for 21 days) inhibits tumor growth .In FVB/n mice, The amount of Targaprimir-96 (2 or 7 mg/kg; i.p.) in plasma peaks is ~4 h. Importantly, even 48 hours postinjection, the concentration of Targaprimir-96 TFA remaining in plasma is much greater than the 50 nM cellular concentration that triggered apoptosis: 1.6 μM for the 2 mg/kg dosage and 1.9 μM for the 7 mg/kg dosage. |
别名 | Targaprimir-96 TFA |
分子量 | 1505.77 |
分子式 | C79H103F3N18O9 |
CAS No. | T13085L |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Targaprimir-96 TFA (1655508-14-7 free base) T13085L Others Targaprimir 96 TFA (1655508 14 7 free base) Targaprimir-96 TFA 1655508-14-7 Targaprimir96 TFA (1655508147 free base) 1655508-14-7 free base Inhibitor inhibitor inhibit